Clinical Trials · NCT05356104
GLP-1 Analogue in Preventing Progression of Small Vessel Disease (GAPP-SVD)
- Phase
- Phase 2
- Recruitment status
- Recruiting
- Sponsor
- Chinese University of Hong Kong
- Enrollment
- 110
- Start date
- May 2022
- Locations
- 2 sites, China, Hong Kong
- Primary endpoint
- Change of Brain Peak Width of Skeletonized Mean Diffusivity